Alliancebernstein L.P. grew its holdings in Intersect ENT Inc (NASDAQ:XENT) by 12.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,466,730 shares of the medical equipment provider’s stock after acquiring an additional 161,723 shares during the quarter. Alliancebernstein L.P.’s holdings in Intersect ENT were worth $47,522,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. GSA Capital Partners LLP acquired a new stake in Intersect ENT in the third quarter worth about $926,000. Schwab Charles Investment Management Inc. boosted its holdings in Intersect ENT by 21.8% in the third quarter. Schwab Charles Investment Management Inc. now owns 115,439 shares of the medical equipment provider’s stock worth $3,596,000 after acquiring an additional 20,700 shares in the last quarter. OxFORD Asset Management LLP acquired a new stake in Intersect ENT in the third quarter worth about $2,371,000. Neuberger Berman Group LLC boosted its holdings in Intersect ENT by 8.0% in the third quarter. Neuberger Berman Group LLC now owns 802,521 shares of the medical equipment provider’s stock worth $24,999,000 after acquiring an additional 59,620 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in Intersect ENT by 18.6% in the third quarter. Russell Investments Group Ltd. now owns 45,315 shares of the medical equipment provider’s stock worth $1,411,000 after acquiring an additional 7,101 shares in the last quarter. 84.49% of the stock is owned by institutional investors and hedge funds.
Intersect ENT Inc (NASDAQ XENT) opened at $38.75 on Wednesday. Intersect ENT Inc has a 12 month low of $14.60 and a 12 month high of $39.30. The stock has a market capitalization of $1,190.00, a PE ratio of -69.20 and a beta of 0.80.
Intersect ENT (NASDAQ:XENT) last announced its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.06. Intersect ENT had a negative return on equity of 14.40% and a negative net margin of 16.99%. The firm had revenue of $29.53 million during the quarter, compared to analysts’ expectations of $29.45 million. analysts forecast that Intersect ENT Inc will post -0.59 EPS for the current fiscal year.
Several equities research analysts have weighed in on XENT shares. Guggenheim reissued a “buy” rating on shares of Intersect ENT in a report on Thursday, March 1st. JPMorgan Chase & Co. raised Intersect ENT from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Canaccord Genuity reissued a “buy” rating and issued a $36.00 price target on shares of Intersect ENT in a report on Monday, December 11th. BidaskClub downgraded Intersect ENT from a “buy” rating to a “hold” rating in a report on Tuesday, February 27th. Finally, Zacks Investment Research raised Intersect ENT from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Five research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $33.38.
In other news, CFO Jeryl L. Hilleman sold 12,835 shares of the firm’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $33.81, for a total value of $433,951.35. Following the completion of the transaction, the chief financial officer now directly owns 25,767 shares in the company, valued at $871,182.27. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Gwen R. Carscadden sold 10,000 shares of the firm’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $34.35, for a total value of $343,500.00. Following the completion of the transaction, the insider now owns 13,856 shares of the company’s stock, valued at $475,953.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 136,310 shares of company stock valued at $4,660,238. Company insiders own 13.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Alliancebernstein L.P. Buys 161,723 Shares of Intersect ENT Inc (XENT)” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/14/alliancebernstein-l-p-buys-161723-shares-of-intersect-ent-inc-xent.html.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT Inc (NASDAQ:XENT).
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.